Polycystic Kidney Disease (PKD) - Drug Pipeline Landscape, 2023

Polycystic Kidney Disease (PKD) - Drug Pipeline Landscape, 2023

Polycystic Kidney Disease (PKD or PCKD) also known as polycystic kidney syndrome, is a genetic disorder. This causes the fluid filled cysts within the kidney. This is a form of chronic kidney disease which results in the reduction of kidney function, which may lead to kidney failure. PKD is mainly of two types: autosomal dominant PKD (ADPKD) and autosomal recessive PKD (ARPKD).

PKD is caused due to the abnormal genes which produces abnormal protein. This abnormal protein has an adverse effect on tubule development.

Signs and symptoms include high blood pressure, abdominal pain, back pain, blood in urine, excessive urination and headaches.

PKD can be diagnosed using imaging test such as CT scan of abdomen, MRI and ultrasound. Genetic testing is also done in some situations. A physical examination is also preferred including liver, heart murmurs and elevated blood pressure.

PKD treatment focuses on the slowing of the disease progression through maintaining normal blood pressure, low-salt intake, weight control, dietary protein restriction. Anti-hypertensive agents, pain killers and antibiotics are recommended.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the Polycystic Kidney Disease (PKD) treatment such as Bardoxolone methyl, Tolvaptan, GLPG2737 and others. Key players involved in the development of therapies to treat Polycystic Kidney Disease (PKD) are Reata Pharmaceuticals Inc, Otsuka Pharmaceutical Co Ltd, Galapagos NV, Sanofi, XORTX Therapeutics Inc and others. Two drugs are under late-stage Phase III clinical trials and three drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development.

Report Highlights

Global Insight Service's, Polycystic Kidney Disease (PKD) - Drug Pipeline Landscape, 2023 report provides an overview of the Polycystic Kidney Disease (PKD) pipeline drugs. This report covers detailed insights on Polycystic Kidney Disease (PKD) drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Polycystic Kidney Disease (PKD) pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.